Navigation Links
Sigma-Aldrich Launches Your Favorite Gene Powered by Ingenuity
Date:1/27/2009

Web Portal Provides Access to Dynamic Library of Life Science Research and Enables Experiment Modeling

ST. LOUIS, Jan. 27 /PRNewswire-FirstCall/ -- Sigma-Aldrich (Nasdaq: SIAL) and Ingenuity Systems today launched Your Favorite Gene powered by Ingenuity, a Web-based biological search portal for exploring dynamic gene-based content (http://www.sigma-aldrich.com/yfg). Based on Ingenuity's extensive library of research findings, Your Favorite Gene powered by Ingenuity positions Sigma-Aldrich's life science products within a content-rich environment of relevant biological and chemical information. The Web site also provides researchers with the capability to model and evaluate prospective experiments in the context of previously published scientific literature.

The new portal is built upon Sigma-Aldrich's leading Your Favorite Gene search engine, and incorporates Ingenuity's Knowledge Base, the world's largest repository of biological and chemical networks. A dramatic departure from the prevalent static search interfaces among life science product providers, this intuitive search tool matches thousands of Sigma-Aldrich products to biological information, presented in dynamic networks.

Researchers and students can search by gene, protein, function, disease, species, tissue or pathway to access a range of previous research findings and biological information including molecular functions, cell regulation, protein domains, and metabolic and signaling pathways. From an initial search, simple navigation allows exploration of broader networks, providing insight into pathway interactions. Researchers can also model prospective experiments in Your Favorite Gene powered by Ingenuity, accessing the findings of previous studies and quickly sourcing the availability of Sigma-Aldrich products relevant to their work.

"Sigma-Aldrich is establishing itself as a destination for the life science community to understand biology and access the resources it needs to continue groundbreaking research," said Dr. David Smoller, President of Sigma-Aldrich's Research Biotech business unit. "We intend Your Favorite Gene powered by Ingenuity to serve as an information hub for researchers and students exploring diseases, functions, and gene pathways, and to match our comprehensive collection of products, kits and reagents to relevant biological information."

Ingenuity's library is comprised of information extracted from a range of leading and specialized scientific journals by a team of Ph.D.-level life scientists. Ingenuity's networks of biological and chemical relationships are manually curated, providing researchers with the most up-to-date findings related to proteins, genes, complexes, drugs, tissues, cells, and diseases of interest. Your Favorite Gene powered by Ingenuity will present select information from Ingenuity's library, with quick links to the larger repository for Ingenuity subscribers.

"Today's increasing emphasis on a systems view of biology is requiring scientists to design their experiments based on a more complete and dynamic understanding of biology," said Jake Leschly, CEO of Ingenuity. "Through Your Favorite Gene powered by Ingenuity, researchers are now able to leverage the breadth of Ingenuity's knowledge and technology to gain scientific insight and to immediately translate this into more effective experimental designs and a better selection of Sigma-Aldrich products."

Your Favorite Gene powered by Ingenuity provides streamlined access to Sigma-Aldrich's extensive portfolio of validated shRNAs, siRNAs, Prestige Antibodies and bioactive small molecule products. The Web portal is free for all researchers and students, and can be accessed at http://www.sigma-aldrich.com/yfg.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Its biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 36 countries and has 8,000 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through innovation and Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit its award-winning Web site at http://www.sigma-aldrich.com.

About Ingenuity Systems: Ingenuity Systems enables researchers to model, analyze, and understand complex biological and chemical systems foundational to human health and disease. All of Ingenuity's products and services have one common goal -- to provide relevant context and understanding to life science researchers. The Ingenuity products include pathways analysis software and knowledge bases for life scientists and bioinformaticians, in addition to business solutions focused on semantic search and enterprise knowledge management infrastructure. Ingenuity was founded in 1998 and is headquartered in Redwood City, California with offices in Germany, Switzerland, France, the United Kingdom, and Japan. www.ingenuity.com.

Cautionary Statement: This release contains forward-looking statements relating to future performance, goals, strategic actions and initiatives and similar intentions and beliefs and other statements regarding the Companies' expectations, goals, beliefs, intentions and the like, which involve assumptions regarding the Companies' operations and conditions in the markets the Companies serve. The Companies do not undertake any obligation to update these forward-looking statements.


'/>"/>
SOURCE Sigma-Aldrich
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Sigma-Aldrich Corporations 4th Quarter 2008 Earnings Conference Call
2. Sigma-Aldrich and Sangamo BioSciences Announce the Achievement of Key Throughput Milestone in Research Reagents Agreement
3. Sigma-Aldrich Acquires Seppro(R) Depletion Technology From GenWay Biotech
4. Sigma-Aldrich Signs Agreement With SouthWest NanoTechnologies to Distribute SWeNT(R) Single-Wall Carbon Nanotubes
5. Sigma-Aldrich Enters Into Research Collaboration Program With D-Finitive Cell Technologies, Inc., to Develop Research Tools for Regenerative Medicine
6. Sigma-Aldrich to Present at the 19th Annual Citi Chemicals Conference Tuesday, December 2, 2008
7. Sigma-Aldrich Introduces MISSION(R) In VIVO QUALITY and iScale Oligos(TM) siRNA, a Superior Quality siRNA Designed for RNAi Research in Animal Models
8. Sigma-Aldrich (Nasdaq: SIAL) Declares Quarterly Dividend
9. Sigma-Aldrich Introduces Methylated DNA Quantification Technology for Epigenetic Research
10. Sigma-Aldrich Releases WTA2, a Transplex Whole Transcriptome Amplification Technology for Degraded RNA Samples
11. Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Md. , March 23, 2017  Northwest ... developing DCVax┬« personalized immune therapies for solid tumor ... the $7.5 million financing it announced last Friday, ... sold to several institutional investors securities totaling 28,843,692 ... per share, and 10,000,000 shares of Class C ...
(Date:3/23/2017)...  BioPharmX Corporation (NYSE MKT: BPMX), a specialty ... today reported financial results for the quarter and ... an update on the company,s clinical development efforts ... are pleased to report that last year was ... Anja Krammer. "We achieved key clinical milestones and ...
(Date:3/23/2017)... -- NetworkNewsWire Editorial Coverage  ... Cancer remains one of the ... care systems, in terms of costs and resources. However, as ... development of innovative and efficient therapies that demonstrate higher chances ... of cancer treatments, a growing number of patients receiving immuno-oncology ...
(Date:3/23/2017)... -- In today,s pre-market research, Stock-Callers.com takes ... industry: Sangamo Therapeutics Inc. (NASDAQ: SGMO), Eyegate Pharmaceuticals Inc. ... Regulus Therapeutics Inc. (NASDAQ: RGLS ). On ... rating on Pharmaceuticals/Biotechnology to "Overweight" from "Market Weight." Learn more about ... ...
Breaking Biology Technology:
(Date:2/14/2017)... N.C. , Feb. 14, 2017  Wake Forest ... M.D., as its new chief executive officer (CEO). Freischlag ... CEO John D. McConnell , M.D., who last ... position at the Medical Center, after leading it since ... the full scope of Wake Forest Baptist,s academic health ...
(Date:2/10/2017)... Feb 10, 2017 Research and ... "Personalized Medicine - Scientific and Commercial Aspects" to ... ... Diagnosis is integrated with therapy for selection of treatment as ... detection and prevention of disease in modern medicine. Biochip/microarray technologies ...
(Date:2/8/2017)... BEDFORD, Mass., Feb. 7, 2017  Aware, Inc. (NASDAQ: ... services, today reported financial results for its quarter and year ... fourth quarter of 2016 was $3.9 million compared to $6.9 ... the fourth quarter of 2016 was $0.6 million compared to ... in the fourth quarter of 2016 was $0.5 million, or ...
Breaking Biology News(10 mins):